Can high-efficacy treatments improve outcomes for people diagnosed with #MultipleSclerosis later in life? Dr Yi Chao Foong @ycfoong.bsky.social from our #MSResearch Flagship explores this in his poster at #ECTRIMS2025 🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025

Our MS Research Flagship's Prof Bruce Taylor is at #ECTRIMS2025! His poster explores how genetic oxidative stress and low Mediterranean diet intake combine to influence MS onset risk. More 👇 🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025 #MultipleSclerosis #MSResearch

Our MS Research Flagship's Himanshu Saraswat is at #ECTRIMS2025! His study investigated whether rare genetic variants in families with multiple MS cases could help explain MS risk. More 👇 🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025 #MultipleSclerosis #MSResearch

Dr Xin Lin from our MS Research Flagship is at #ECTRIMS2025! His poster reveals how genetic structural variation in complement component 4 affects risk of MS onset and disability progression. 🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025 #MultipleSclerosis #MSResearch

Want to turbo charge your #science career with a #PhD? Find out if people living with #MS are ageing well in this project at @menzies-research.bsky.social www.utas.edu.au/research/deg...

Retinal thinning on OCT as a marker of PIRA - #multiplesclerosis #MS tinyurl.com/24k2nja7

Absolute pleasure to be part of this controversies in MS debate! Of course, real life practice sits in between the two positions, but much food for thought on both ends of the spectrum. #MS #multiplesclerosis #neurology journals.sagepub.com/doi/10.1177/...

For people with existing autoimmune disorders who take immune checkpoint inhibitors, the risk of relapse appears to be much higher with myasthenia gravis (12 of 18 [67%], often severe) vs only 8 of 45 [18%] with multiple sclerosis. Why? pubmed.ncbi.nlm.nih.gov/40465294/

🧠🌏 NEW PAPER: We surveyed Australian & New Zealand neurologists about climate change and brain health. Here's what we found 🧵 OA paper here: www.sciencedirect.com/science/arti...

Interesting study that shows trough NTZ levels affect JCV seroconversion, with low trough levels reducing risk of seroconversion #multiplesclerosis #MS jnnp.bmj.com/content/earl...

New paper! How does cognition change over time in #MS? We analyzed longitudinal data using the iPad-based Processing speed test (PST). Full #OA paper here - onlinelibrary.wiley.com/doi/full/10....

Chance for tasmanian RACP members to give feedback on the upcoming 20 year tassie preventative health strategy - www.racp.edu.au/policy-and-a... #RACP #politas #Tasmania

Curious that this isn't bigger news -- Australia's most iconic multi-day walking track, rapidly being burnt out. This was 11:00 am yesterday, just south of Cradle Mountain: browser.dataspace.copernicus.eu?zoom=12&lat=...

ANZ recommendations on MS management - congrats Jess, a comprehensive and contemporary look at optimal MS management! www.mja.com.au/journal/2025...

yet another failed deescalation trial - not particularly surprising given fingolimod & natalizumab drove the results. #multiplesclerosis #neurology #MS pmc.ncbi.nlm.nih.gov/articles/PMC...

A randomized trial showed Factor XIa inhibitor (abelacimab) compared with the currently used Factor Xa blocking agents (rivoroxaban) for atrial fibrillation led to significantly less bleeding events, leading to early trial termination nejm.org/doi/full/10....

ECTRIMS recommendations of AHSCT for MS and NMOSD: www.nature.com/articles/s41...

🧠 New paper! How does upper limb function change over time in #MS? We analyzed longitudinal data using the iPad-based Manual Dexterity Test (MDT). Full #OA paper here: onlinelibrary.wiley.com/doi/10.1111/...

DOT-MS: #MS DMT discontinuation trial - stopped early due to increased clinical/radiological relapse in discontinuation group (17.8%!!). On platform therapies with median age 55 and 5 years of disease stability jamanetwork.com/journals/jam...

I give this article an A+ just based on the title: "Sportizumab - Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial" www.sciencedirect.com/science/arti...

New paper! 📜 Happy to share our paper on #COVID infection on #MS disease activity using MSBase data! COVID was linked to a higher relapse rate and shorter time to first relapse. #multiplesclerosis #OA paper here: tinyurl.com/ymn3fp6k

Yes, I really want you to get your COVID19 vaccine. pubmed.ncbi.nlm.nih.gov/39525878/